Ablynx announced that it has entered into a research collaboration and global exclusive licensing agreement with Sanofi initially focused on developing and commercialising Nanobody®-based therapeutics for the treatment of various immune-mediated inflammatory diseases.

SHRINK study to evaluate the synergetic effect of the concurrent administration of CYAD-01 (CAR-T NKG2D) with standard chemotherapy in patients suffering from metastatic colorectal cancer.

In a discovery with broad implications for the specialty chemicals industries like pharmaceuticals, researchers at Rice University and the California Institute of Technology have succeeded in a decades-long quest to make left- and right-handed versions of a molecular sieve, one of the most-used industrial, solid materials.

Ensuring safe working conditions for all employees in the biotech industry in Belgium, is the joint ambition of bio.be/essenscia, the federation of Belgian life sciences companies, and the Belgian Biosafety Professionals (BBP), the professional association of experts in biosafety. Both organizations signed a Memorandum of Understanding to collaborate more closely on safety aspects in biotechnology, for employees in both R&D and production.

Belgium counts more than 1,000 new HIV infections each year, which is a lot compared to other European countries. Fortunately, an HIV infection is no longer a death sentence. With the available treatments, an HIV-positive person lives almost as long as someone who is not infected with the virus, on the condition that you daily take virus inhibitors. However, this increases the number of HIV positive people from year to year, which also increases the annual necessary budget for HIV treatment.

MDx Health gains market access of the Middle East via partner IPS Genomix.

Singapore's Agency for Science, Technology and Research will develop the new assay while Biocartis will be responsible for commercialisation.

Methylation specialist MDx Health brings its third assay to the market. The AssureMDx liquid biopsy assay is able to detect bladder cancer in a urine sample.

The anti-inflammatory molecule enters yet another phase II trial.

The Belgian developer of the DropSense system Trinean is being acquired by American lab devices developer Unchained Labs.